Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomised, Double-Blind, Placebocontrolled Study To Investigate The Effects Of ZD1839 (IRESSA™) On Cell Proliferation In Oestrogen And Progesterone Receptor Negative Breast Cancer Prior To Surgery

NCT00252811 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00252811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00252811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomised, Double-Blind, Placebocontrolled Study To Investigate The Effects Of ZD1839 (IRESSA™) On Cell Proliferation In Oestrogen And Progesterone Receptor Negative Breast Cancer Prior To Surgery
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Withdrawn
Start date
February 29, 2004
Completion date
Not reported
Enrollment
60
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer